These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27659862)

  • 1. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
    Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus.
    Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Acta Biomater; 2016 Sep; 41():161-8. PubMed ID: 27063491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery.
    Marasini N; Giddam AK; Khalil ZG; Hussein WM; Capon RJ; Batzloff MR; Good MF; Toth I; Skwarczynski M
    Nanomedicine (Lond); 2016 Dec; 11(24):3223-3235. PubMed ID: 27830630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of an inactivated avian influenza virus vaccine adjuvanted with poly(D,L-lactic-co-glycolic acid) encapsulated CpG ODN induces protective immune responses in chickens.
    Singh SM; Alkie TN; Nagy É; Kulkarni RR; Hodgins DC; Sharif S
    Vaccine; 2016 Sep; 34(40):4807-13. PubMed ID: 27543454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles.
    Pan L; Zhang Z; Lv J; Zhou P; Hu W; Fang Y; Chen H; Liu X; Shao J; Zhao F; Ding Y; Lin T; Chang H; Zhang J; Zhang Y; Wang Y
    Int J Nanomedicine; 2014; 9():5603-18. PubMed ID: 25506214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
    Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
    J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
    Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA
    Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus.
    Marasini N; Ghaffar KA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Curr Drug Deliv; 2017; 14(5):701-708. PubMed ID: 27440071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modular virus-like particles for sublingual vaccination against group A streptococcus.
    Seth A; Kong IG; Lee SH; Yang JY; Lee YS; Kim Y; Wibowo N; Middelberg AP; Lua LH; Kweon MN
    Vaccine; 2016 Dec; 34(51):6472-6480. PubMed ID: 27866769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: A promising alternate to traditional adjuvants.
    Singh D; Somani VK; Aggarwal S; Bhatnagar R
    Mol Immunol; 2015 Dec; 68(2 Pt A):272-9. PubMed ID: 26442664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
    Pawar D; Mangal S; Goswami R; Jaganathan KS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):550-9. PubMed ID: 23831265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
    Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remote glucosyltransferase-microparticle vaccine delivery induces protective immunity in the oral cavity.
    Smith DJ; Lam A; Barnes LA; King WF; Peacock Z; Wise DL; Trantolo DJ; Taubman MA
    Oral Microbiol Immunol; 2003 Aug; 18(4):240-8. PubMed ID: 12823800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
    Nevagi RJ; Khalil ZG; Hussein WM; Powell J; Batzloff MR; Capon RJ; Good MF; Skwarczynski M; Toth I
    Acta Biomater; 2018 Oct; 80():278-287. PubMed ID: 30266637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.
    Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J
    PLoS One; 2017; 12(4):e0175707. PubMed ID: 28414746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus.
    Marasini N; Giddam AK; Ghaffar KA; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Nanomedicine (Lond); 2016 May; 11(10):1223-36. PubMed ID: 27077314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of immunogenicity of avian influenza antigens encapsulated in PLGA nanoparticles following mucosal and subcutaneous delivery in chickens.
    Alkie TN; Yitbarek A; Taha-Abdelaziz K; Astill J; Sharif S
    PLoS One; 2018; 13(11):e0206324. PubMed ID: 30383798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus.
    Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Med Chem; 2016; 13(1):22-27. PubMed ID: 27449794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.